Citable company snapshot
Thermo Fisher Scientific's latest SEC-sourced 2026-03-28 period shows $11.01B in revenue and $1.65B in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 28, 2026 | $11.01B | $12.21B | -9.9% |
| xbrl:OperatingIncomeLoss | Mar 28, 2026 | $1.86B | $2.25B | -17.4% |
| xbrl:NetIncomeLoss | Mar 28, 2026 | $1.65B | $1.96B | -15.9% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 28, 2026 | $1.19B | $3.46B | -65.5% |
| Free Cash Flow (computed) | Mar 28, 2026 | $816.00M | $2.99B | -72.7% |
Source: SEC EDGAR XBRL; period Mar 28, 2026; filed May 1, 2026; accession 0000097745-26-000092.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
